Terms: = Brain cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Clinical Outcome
32 results:
1. clinical features and outcomes of advanced her2+ esophageal/GEJ cancer with brain metastasis.
Liang K; Feliciano JL; Marrone KA; Murray JC; Hann CL; Anagnostou V; Tackett SA; Shin EJ; Hales RK; Voong KR; Battafarano RJ; Yang SC; Broderick SR; Ha JS; Forde PM; Brahmer JR; Lam VK
ESMO Open; 2024 Jan; 9(1):102199. PubMed ID: 38071928
[TBL] [Abstract] [Full Text] [Related]
2. Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review.
Müller V; Bartsch R; Lin NU; Montemurro F; Pegram MD; Tolaney SM
Cancer Treat Rev; 2023 Apr; 115():102527. PubMed ID: 36893691
[TBL] [Abstract] [Full Text] [Related]
3. clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for her2-positive metastatic breast cancer in a real-life cohort.
Collet L; Eberst L; Ludovic G; Debled M; Hrab L; Mouret-Reynier MA; Desmoulins I; Goncalves A; Campone M; Ferrero JM; Brain E; Uwer L; Eymard JC; Dieras V; Simon G; Leheurteur M; Dalenc F; Vanlemmens L; Darlix A; Arnedos M; Bachelot T
Breast Cancer; 2023 Mar; 30(2):329-341. PubMed ID: 36630013
[TBL] [Abstract] [Full Text] [Related]
4. New treatment strategies for human epidermal growth factor receptor 2-positive breast cancer in 2023.
Banys-Paluchowski M; Krawczyk N; Stickeler E; Müller V; Fehm T
Curr Opin Obstet Gynecol; 2023 Feb; 35(1):54-61. PubMed ID: 36239554
[TBL] [Abstract] [Full Text] [Related]
5. Ventriculoperitoneal Shunt for CNS Metastasis in Breast cancer: clinical outcomes Based on Intrinsic Subtype.
Kim HK; Lee HS; Heo MH; Kim JY; Ahn JS; Im YH; Lee JI; Park YH
Clin Breast Cancer; 2021 Aug; 21(4):e402-e414. PubMed ID: 33526378
[TBL] [Abstract] [Full Text] [Related]
6. Long-term clinical outcome of Trastuzumab and Lapatinib for her2-positive Metastatic Colorectal cancer.
Tosi F; Sartore-Bianchi A; Lonardi S; Amatu A; Leone F; Ghezzi S; Martino C; Bencardino K; Bonazzina E; Bergamo F; Fenocchio E; Martinelli E; Troiani T; Siravegna G; Mauri G; Torri V; Marrapese G; Valtorta E; Cassingena A; Cappello G; Bonoldi E; Vanzulli A; Regge D; Ciardiello F; Zagonel V; Bardelli A; Trusolino L; Marsoni S; Siena S
Clin Colorectal Cancer; 2020 Dec; 19(4):256-262.e2. PubMed ID: 32919890
[TBL] [Abstract] [Full Text] [Related]
7. clinical outcome of patients with brain metastases from breast cancer - A population based study over 21 years.
Thulin A; Rönnerman E; Zhang C; De Lara S; Chamalidou C; Schoenfeldt A; Andersson C; Kovács A; Enlund F; Linderholm B
Breast; 2020 Apr; 50():113-124. PubMed ID: 32145571
[TBL] [Abstract] [Full Text] [Related]
8. The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).
De Lara S; Nyqvist J; Werner Rönnerman E; Helou K; Kenne Sarenmalm E; Einbeigi Z; Karlsson P; Parris TZ; Kovács A
BMC Cancer; 2019 Feb; 19(1):187. PubMed ID: 30819139
[TBL] [Abstract] [Full Text] [Related]
9. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/her2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S
Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832
[TBL] [Abstract] [Full Text] [Related]
10. T-DM1 and brain metastases: clinical outcome in her2-positive metastatic breast cancer.
Fabi A; Alesini D; Valle E; Moscetti L; Caputo R; Caruso M; Carbognin L; Ciccarese M; La Verde N; Arpino G; Cannita K; Paris I; Santini D; Montemurro F; Russillo M; Ferretti G; Filippelli G; Rossello R; Fabbri A; Zambelli A; Leonardi V; D'Ottavio AM; Nisticò C; Stani S; Giampaglia M; Scandurra G; Catania G; Malaguti P; Giannarelli D; Cognetti F
Breast; 2018 Oct; 41():137-143. PubMed ID: 30092500
[TBL] [Abstract] [Full Text] [Related]
11. Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for her2+:ERα- breast cancer.
Liu JC; Zacksenhouse M; Eisen A; Nofech-Mozes S; Zacksenhaus E
PLoS One; 2017; 12(6):e0179223. PubMed ID: 28632792
[TBL] [Abstract] [Full Text] [Related]
12. clinical outcome and molecular characterization of brain metastases from esophageal and gastric cancer: a systematic review.
Ghidini M; Petrelli F; Hahne JC; De Giorgi A; Toppo L; Pizzo C; Ratti M; Barni S; Passalacqua R; Tomasello G
Med Oncol; 2017 Apr; 34(4):62. PubMed ID: 28315230
[TBL] [Abstract] [Full Text] [Related]
13. Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast cancer Cells Influencing clinical outcomes.
Marusyk A; Tabassum DP; Janiszewska M; Place AE; Trinh A; Rozhok AI; Pyne S; Guerriero JL; Shu S; Ekram M; Ishkin A; Cahill DP; Nikolsky Y; Chan TA; Rimawi MF; Hilsenbeck S; Schiff R; Osborne KC; Letai A; Polyak K
Cancer Res; 2016 Nov; 76(22):6495-6506. PubMed ID: 27671678
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic impact of breast cancer subtypes in elderly patients.
Bergen ES; Tichy C; Berghoff AS; Rudas M; Dubsky P; Bago-Horvath Z; Mader RM; Exner R; Gnant M; Zielinski CC; Steger GG; Preusser M; Bartsch R
Breast Cancer Res Treat; 2016 May; 157(1):91-9. PubMed ID: 27107570
[TBL] [Abstract] [Full Text] [Related]
15. miR-141-Mediated Regulation of brain Metastasis From Breast cancer.
Debeb BG; Lacerda L; Anfossi S; Diagaradjane P; Chu K; Bambhroliya A; Huo L; Wei C; Larson RA; Wolfe AR; Xu W; Smith DL; Li L; Ivan C; Allen PK; Wu W; Calin GA; Krishnamurthy S; Zhang XH; Buchholz TA; Ueno NT; Reuben JM; Woodward WA
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27075851
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic Value of Treatment Setting in Patients With cancer Having Pulmonary Embolism: Comparison With the Pulmonary Embolism Severity Index.
Ahn S; Lee YS; Kim WY; Lim KS; Lee JL
Clin Appl Thromb Hemost; 2017 Sep; 23(6):615-621. PubMed ID: 26759372
[TBL] [Abstract] [Full Text] [Related]
17. Co-overexpression of her2/HER3 is a predictor of impaired survival in breast cancer patients.
Berghoff AS; Bartsch R; Preusser M; Ricken G; Steger GG; Bago-Horvath Z; Rudas M; Streubel B; Dubsky P; Gnant M; Fitzal F; Zielinski CC; Birner P
Breast; 2014 Oct; 23(5):637-43. PubMed ID: 25017122
[TBL] [Abstract] [Full Text] [Related]
18. Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain.
Rao PS; Labhart M; Mayhew SL; Thirumala S; Rao US
Tumour Biol; 2014 Jul; 35(7):7267-73. PubMed ID: 24777335
[TBL] [Abstract] [Full Text] [Related]
19. Survival of patients with metastatic breast cancer: a single-centre experience.
D'hondt R; Spoormans I; Neyens N; Mortier N; Van Aelst F
Acta Clin Belg; 2014 Jun; 69(3):194-9. PubMed ID: 24641516
[TBL] [Abstract] [Full Text] [Related]
20. Nuclear T-STAR protein expression correlates with her2 status, hormone receptor negativity and prolonged recurrence free survival in primary breast cancer and decreased cancer cell growth in vitro.
Sernbo S; Borrebaeck CA; Uhlén M; Jirström K; Ek S
PLoS One; 2013; 8(7):e70596. PubMed ID: 23923007
[TBL] [Abstract] [Full Text] [Related]
[Next]
